Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1633575 10.3389/fphar.2025.1633575 Pharmacology Correction Correction: Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions Balboa et al. 10.3389/fphar.2025.1633575 Balboa Elisa 1 * Saud Faride 1 Parra-Ruiz Claudia 2 Fuente Marjorie de la 1 Landskron Glauben 1 Zanlungo Silvana 2 1 Center for Biomedical Research, Universidad Finis Terrae, Santiago, Chile 2 Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Edited and reviewed by: Anna Cantalupo, Mount Sinai Hospital, United States

 *Correspondence: Elisa Balboa, ebalboa@uft.cl 25 06 2025 2025 16 1633575 23 05 2025 12 06 2025 Copyright © 2025 Balboa, Saud, Parra-Ruiz, Fuente, Landskron and Zanlungo. 2025 Balboa, Saud, Parra-Ruiz, Fuente, Landskron and Zanlungo

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions by Balboa E, Saud F, Parra-Ruiz C, de la Fuente M, Landskron G and Zanlungo S (2024). Front. Pharmacol. 15:1406784. doi: 10.3389/fphar.2024.1406784 hepatic steatosis lipophagy lutein TFEB StARD3 lipid droplet section-at-acceptance Gastrointestinal and Hepatic Pharmacology

In the published article, there was an error in Figure 2 as published. In the section of the figure labeled as “Step 2,” where STARD3 is shown at the plasma membrane, it is depicted with its N-terminal and C-terminal domains oriented toward the extracellular space. However, both the N- and C-terminal domains of STARD3 must be cytoplasmic. The corrected Figure 2 and its caption appear below.

Proposed mechanisms involved in lutein-mediated hepatoprotective effects. We propose that independent of its antioxidant and antiapoptotic activity, lutein stimulates LD autophagy in the liver, reducing their accumulation and improving steatosis. This action is mediated through the activation of TFEB. Given lutein’s hydrophobic nature as a carotenoid, an intracellular transporter is required to exert its activity within the cell. We propose that STARD3 serves as this transporter. 1) To enter the cell, lutein in lipoproteins, primarily QM and HDL, binds to their transporters on the hepatocyte membrane (SRBI, LDLR, LRP1). 2) Additionally, lutein may directly enter the cell by binding to STARD3 on the plasma membrane. 3) Once inside the cell, lutein bound to STARD3 would directly or indirectly interact with TFEB, mediating its activation. 4) Another pathway for lutein entry involves endosomal uptake, where it binds to STARD3 in the lysosome, activating TFEB via the MCOLN1/Ca2+/calcineurina pathway.

Diagram illustrating how lutein (LUT), derived from vegetables like pumpkin and spinach, may reduce hepatic steatosis leading to a healthy liver. Lutein interacts with HDL/QM and influences cellular processes involving StarD3, lysosome, TFEB, and calcineurin, ultimately regulating lysosomal and autophagic genes.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.